Panel Discussion: Defining Clinical Endpoints & Exploring Surrogates for HBV Functional Cure

Time: 8:30 am
day: Day Two


• Reflecting cccDNA activity and assessing durability of hepatitis B surface antigen seroclearance

• Outlining parameters for acceptable and clinically meaningful hepatitis B surface antigen loss and opportunities to implement alternative surrogate endpoints

• Future directions: looking towards a sterilizing cure